Important information

This information is not intended for, and shall not be accessible, published, distributed or circulated to persons resident or located in the United States of America, Canada, Japan or Australia, and does not constitute an offer to sell or the solicitation of an offer to purchase or acquire securities of Onxeo in the United States of America, Canada, Japan or Australia.

With respect to Member States of the European Economic Area that have transposed European Directive 2003/71/EC of the European Parliament and European Council of 4 November 2003 (as amended in particular by Directive 2010/73/EU to the extent that the said Directive has been transposed into each Member State of the European Economic Area) (the “Prospectus Directive”), no action has been taken or will be taken to permit a public offering of the securities of Onxeo requiring the publication of a prospectus in any Member State, other than in France and Denmark. Therefore, such securities may not be and shall not be offered in any Member State (other than in France and in Denmark) other than in accordance with the exemptions of Article 3(2) of the Prospective Directive to the extent they have been transposed by the Member State or, otherwise, in cases not requiring a prospectus under Article 3(2) of the Prospective Directive and/or the applicable regulations in such Member State.

Shares and other securities in Onxeo may not be sold in the United States of America unless the offer is registered with the Securities and Exchange Commission under the U.S. Securities Act 1933, as amended, or exemption from such registration is granted. Onxeo does not intend to register an offer of its securities in the United States of America nor does it intend to make a public offer of its securities in the United States of America.

This information is solely addressed to, and intended for persons who are (i) outside the United Kingdom, (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), (iii) high net worth entities and other such persons falling within Article 49(2)(a) to (d) of the Order (“high net worth companies”, “unincorporated associations”, etc.) or (iv) other persons to whom an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the Financial Services and Market Act 2000) may otherwise lawfully be communicated or caused to be communicated (all such persons in (i), (ii), (iii) and (iv) together being referred to as “Relevant Persons”). Securities are intended solely for Relevant Persons and any invitation, offer or contract for the subscription, purchase or acquisition of the securities mentioned on the website may only be addressed to or entered into with Relevant Persons. No person other than a Relevant Person may act on the basis of or rely on this website or any information contained therein.

Access to the information and documents contained in the following pages may be illegal in certain countries and only certain categories of persons may be authorized to access this information and these documents. Any person resident in a country other than France, the United States of America, Canada, Japan or Australia who wishes to access the information and documents contained on this website must first satisfy him or herself that he or she is not subject to local laws or regulations prohibiting or restricting such right of access or requiring registration or approval of the securities in order to acquire them. No registration or approval has been or will be obtained outside France. The Company will not accept any liability arising out of the breach by any person of applicable laws or regulations.

I therefore certify that:

(1) I am not a resident of the United States of America, Canada, Australia or Japan nor am I currently physically present in any one of those countries;

(2) I am neither resident not currently physically present in any Member State of the European Economic Area that has transposed European Directive 2003/71/EC, or, if I am, I am a “Qualified Investor” within the meaning of the Prospectus Directive;

(3) I am not resident in the United Kingdom nor am I currently physically present in the United Kingdom or, if I am, I am a Relevant Person; and

(4) I am authorized to access the information and documents presented on this website without being subject to any legal restriction and without any further action being necessary on the part of Onxeo.

I have read and understood the above declarations and certify below that they are accurate, and hereby undertake to comply with all the conditions set forth on this page.

V – I confirm X – I do not confirm